Neil Cohen - 18 May 2022 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Director
Signature
/s/ Neil Cohen
Issuer symbol
CMMB
Transactions as of
18 May 2022
Net transactions value
+$6,380
Form type
4
Filing time
19 May 2022, 16:02:33 UTC
Previous filing
15 Mar 2022
Next filing
18 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMMB American Depositary Shares Purchase $6,380 +2,000 +19% $3.19 12,409 18 May 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,820 $0.000000 6,820 07 Mar 2022 American Depositary Shares 6,820 $3.53 Direct F1, F4, F5
transaction CMMB Option to Purchase American Depositary Shares Award $0 +11,884 $0.000000 11,884 19 Apr 2021 American Depositary Shares 11,884 $27.26 Direct F1, F4, F6
transaction CMMB Option to Purchase American Depositary Shares Award $0 +688 $0.000000 688 16 Mar 2021 American Depositary Shares 688 $13.17 Direct F1, F4, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2 The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
F3 Includes the previously reported 10,409 ADSs of the Company, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on March 15, 2022.
F4 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F5 These options vest and become exercisable in their entirety on March 16, 2023 subject to the Reporting Person's continued service.
F6 These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
F7 These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.